A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of ASA404 in Combination With Docetaxel in Second-Line Treatment of Patients With Locally Advanced or Metastatic (Stage IIIb/IV) Non-Small Cell Lung Cancer (NSCLC).

Trial Profile

A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of ASA404 in Combination With Docetaxel in Second-Line Treatment of Patients With Locally Advanced or Metastatic (Stage IIIb/IV) Non-Small Cell Lung Cancer (NSCLC).

Discontinued
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2015

At a glance

  • Drugs Vadimezan (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms ATTRACT-2
  • Most Recent Events

    • 11 Nov 2010 Interim results from an Independent Data Monitoring Committee have been reported in a Novartis media realease.
    • 11 Nov 2010 Primary endpoint 'Overall-survival' has not been met according to a Novartis media release.
    • 11 Nov 2010 Status changed from active, no longer recruiting to discontinued according to an Antisoma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top